Authors
Latest:
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA ImagingExperts weigh in on the practical applications of PSMA PET imaging
Latest:
Overview of the Second-Line nccRCC Treatment LandscapePanelists discuss the challenges of treating non–clear cell renal cell carcinoma (nccRCC) after first-line progression, emphasizing the limited second-line options, the emerging use of immunotherapy (IO) and combination regimens, the need for subtype-specific strategies, and the critical role of clinical trial enrollment to advance care in this heterogeneous disease.
Latest:
Ivonescimab Displays Preclinical Feasibility in Frontline ccRCCThe investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Latest:
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
TAR-200 Might Be “Best in Class” for BCG-Unresponsive High-Risk NMIBCResults from cohort 4 of the phase 2 SunRISe-1 trial showed TAR-200 elicited a 6- and 9-month DFS rate of 85.3% and 81.1%, respectively, in BCG-unresponsive NMIBC.
Latest:
Looking Ahead in R/R FL: Unmet Needs and What’s NextPanelists discuss how unmet needs in relapsed/refractory follicular lymphoma (R/R FL), including durability of responses, adverse effect management, personalized treatment, resistance to therapy, and access to care, are driving exciting developments in emerging targeted therapies, improved CAR T technologies, combination approaches, and efforts to enhance access and affordability for patients.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLCJames Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Latest:
Jonathan Spicer, MD, PhD, Discusses Multidisciplinary Communication for Treating Resectable NSCLC With Neoadjuvant ImmunotherapyCancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.
Latest:
Profilin 1 Protein and Its Implications for CancersProfilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Asciminib Appears to Benefit All Chronic Myeloid Leukemia SubgroupsCompared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Frontline Combination Therapy Intensification May Improve Survival in NSCLCHigher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
